.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Teva
Express Scripts
Healthtrust
Johnson and Johnson
US Department of Justice
Accenture
Moodys
Boehringer Ingelheim
Mallinckrodt

Generated: December 13, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,629,297

« Back to Dashboard

Claims for Patent: 5,629,297

Title: Medicament for treating gastrointestinal disorders
Abstract:The use is described of both (i) ranitidine bismuth citrate and (ii) one or more Helicobacter pylori-inhibiting antibiotics in treating or preventing gastrointestinal disorders. Pharmaceutical compositions containing both (i) and (ii) and methods for the preparation of pharmaceutical compositions containing (i) and (ii) are also described.
Inventor(s): McColm; Andrew A. (Greenford, GB)
Assignee: Glaxo Group Limited (GB)
Application Number:08/462,584
Patent Claims: 1. A method for treating gastrointestinal disorders caused or mediated by H. pylori infections in humans or animals which comprises administering to a human or animal in need thereof an amount of ranitidine bismuth citrate effective against H. pylori in combination with a pharmaceutically acceptable carrier and an amount of clarithromycin effective against H. pylori in combination with a pharmaceutically acceptable carrier, said ranitidine bismuth citrate and said clarithromycin being administered in relative amounts such that the combination provides a greater than additive effect, said administration being concurrent or nonconcurrent.

2. A method according to claim 1 wherein the gastrointestinal disorder treated is a non-ulcerative one.

3. A method according to claim 1 wherein the gastrointestinal disorder treated is gastritis, non-ulcer dyspepsia, esophagal reflux disease or gastric motility disorder.

4. A method according to claim 1 wherein the gastrointestinal disorder treated is peptic ulcer disease.

5. A method according to claim 1 wherein from 150 mg to 1.5 g of ranitidine bismuth citrate is administered one to four times per day.

6. A method according to claim 5 wherein from 200 to 800 mg of ranitidine bismuth citrate is administered one to four times per day.

7. A method according to claim 1 wherein the administration is concurrent.

8. A method according to claim 7 wherein the ranitidine bismuth citrate and the clarithromycin are administered within one hour of each other.

9. A method according to claim 8 wherein the ranitidine bismuth citrate and the clarithromycin are administered within five minutes of each other.

10. A method according to claim 1 wherein the administration of the ranitidine bismuth citrate and the administration of the clarithromycin are both oral.

11. A method according to claim 1 wherein the ranitidine bismuth citrate is administered orally and the clarithromycin is administered parenterally.

12. A method according to claim 1 wherein the ranitidine bismuth citrate and the clarithromycin are both contained in a twin pack dispenser prior to administration to the human or animal.

13. A method according to claim 1 wherein the administration is nonconcurrent.

14. A method according to claim 1 wherein the ranitidine bismuth citrate is administered for four to eight weeks and the clarithromycin is administered for one to two weeks.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Julphar
Harvard Business School
Boehringer Ingelheim
Moodys
Dow
Chubb
AstraZeneca
Novartis
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot